Literature DB >> 33613116

Dihydroartemisinin: A Potential Natural Anticancer Drug.

Xiaoshuo Dai1, Xiaoyan Zhang1,2,3, Wei Chen1,2, Yihuan Chen1, Qiushuang Zhang1, Saijun Mo1,2, Jing Lu1,2,3.   

Abstract

Dihydroartemisinin (DHA) is an active metabolite of artemisinin and its derivatives (ARTs), and it is an effective clinical drug widely used to treat malaria. Recently, the anticancer activity of DHA has attracted increasing attention. Nevertheless, there is no systematic summary on the anticancer effects of DHA. Notably, studies have shown that DHA exerts anticancer effects through various molecular mechanisms, such as inhibiting proliferation, inducing apoptosis, inhibiting tumor metastasis and angiogenesis, promoting immune function, inducing autophagy and endoplasmic reticulum (ER) stress. In this review, we comprehensively summarized the latest progress regarding the anticancer activities of DHA in cancer. Importantly, the underlying anticancer molecular mechanisms and pharmacological effects of DHA in vitro and in vivo are the focus of our attention. Interestingly, new methods to improve the solubility and bioavailability of DHA are discussed, which greatly enhance its anticancer efficacy. Remarkably, DHA has synergistic anti-tumor effects with a variety of clinical drugs, and preclinical and clinical studies provide stronger evidence of its anticancer potential. Moreover, this article also gives suggestions for further research on the anticancer effects of DHA. Thus, we hope to provide a strong theoretical support for DHA as an anticancer drug. © The author(s).

Entities:  

Keywords:  Apoptosis; Cancer; Clinical trail; Combination medication; Dihydroartemisinin; Proliferation

Mesh:

Substances:

Year:  2021        PMID: 33613116      PMCID: PMC7893584          DOI: 10.7150/ijbs.50364

Source DB:  PubMed          Journal:  Int J Biol Sci        ISSN: 1449-2288            Impact factor:   6.580


  117 in total

1.  Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer.

Authors:  Jing-Jing Liu; Wei Tang; Min Fu; Xiao-Qing Gong; Liang Kong; Xue-Min Yao; Ming Jing; Fu-Yi Cai; Xue-Tao Li; Rui-Jun Ju
Journal:  Artif Cells Nanomed Biotechnol       Date:  2019-12       Impact factor: 5.678

Review 2.  Epidemiology and treatment patterns of epithelial ovarian cancer.

Authors:  Philip Jessmon; Talia Boulanger; Wei Zhou; Pallavi Patwardhan
Journal:  Expert Rev Anticancer Ther       Date:  2017-03-22       Impact factor: 4.512

Review 3.  Neurotoxicity and artemisinin compounds do the observations in animals justify limitation of clinical use?

Authors:  A D Dayan
Journal:  Med Trop (Mars)       Date:  1998

Review 4.  Anticancer Activity of Artemisinin and its Derivatives.

Authors:  Silvia Slezakova; Jana Ruda-Kucerova
Journal:  Anticancer Res       Date:  2017-11       Impact factor: 2.480

5.  Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells.

Authors:  Qin He; Jinxue Shi; Xiao-Ling Shen; Jie An; Hong Sun; Lu Wang; Ying-Jie Hu; Qing Sun; Lin-Chun Fu; M Saeed Sheikh; Ying Huang
Journal:  Cancer Biol Ther       Date:  2010-05-18       Impact factor: 4.742

Review 6.  From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy.

Authors:  Thomas Efferth
Journal:  Semin Cancer Biol       Date:  2017-02-28       Impact factor: 15.707

7.  Artesunate combinations for treatment of malaria: meta-analysis.

Authors:  M Adjuik; A Babiker; P Garner; P Olliaro; W Taylor; N White
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

8.  Phospho-TCTP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells.

Authors:  Maria Lucibello; Sara Adanti; Ester Antelmi; Dario Dezi; Stefania Ciafrè; Maria Luisa Carcangiu; Manuela Zonfrillo; Giuseppe Nicotera; Lorenzo Sica; Filippo De Braud; Pasquale Pierimarchi
Journal:  Oncotarget       Date:  2015-03-10

9.  Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein.

Authors:  Xiaoguang Li; Qian Ba; Yanling Liu; Qingxi Yue; Peizhan Chen; Jingquan Li; Haibing Zhang; Hao Ying; Qiurong Ding; Haiyun Song; Hong Liu; Ruiwen Zhang; Hui Wang
Journal:  Cell Discov       Date:  2017-11-21       Impact factor: 10.849

10.  NF-KappaB Pathway Is Involved in Bone Marrow Stromal Cell-Produced Pain Relief.

Authors:  Wei Guo; Satoshi Imai; Jia-Le Yang; Shiping Zou; Huijuan Li; Huakun Xu; Kamal D Moudgil; Ronald Dubner; Feng Wei; Ke Ren
Journal:  Front Integr Neurosci       Date:  2018-10-16
View more
  11 in total

1.  Exploration of the Effect and Potential Mechanism of Echinacoside Against Endometrial Cancer Based on Network Pharmacology and in vitro Experimental Verification.

Authors:  Wan Shu; Ziwei Wang; Rong Zhao; Rui Shi; Jun Zhang; Wei Zhang; Hongbo Wang
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

2.  Effects of dihydroartemisinin combined with cisplatin on proliferation, apoptosis and migration of HepG2 cells.

Authors:  Qi Rao; Ruochan Li; He Yu; Lei Xiang; Bin He; Fenghua Wu; Gang Zhao
Journal:  Oncol Lett       Date:  2022-06-22       Impact factor: 3.111

3.  Suppression of NLRP3 Inflammasome by Dihydroarteannuin via the HIF-1α and JAK3/STAT3 Signaling Pathway Contributes to Attenuation of Collagen-Induced Arthritis in Mice.

Authors:  Mingying Zhang; Danbin Wu; Jia Xu; Lijuan Liu; Wei Jiao; Jiahui Yu; Guangxing Chen
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

4.  A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin.

Authors:  Xiao-Xin Yang; Xiang Xu; Mei-Fang Wang; Hua-Zhen Xu; Xing-Chun Peng; Ning Han; Ting-Ting Yu; Liu-Gen Li; Qi-Rui Li; Xiao Chen; Yu Wen; Tong-Fei Li
Journal:  J Nanobiotechnology       Date:  2022-05-14       Impact factor: 9.429

5.  Dihydroartemisinin Inhibits Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular AMD.

Authors:  Xun Li; Sheng Gao; Yun Zhang; Mei Xin; Cheng Zuo; Naihong Yan; Qingjie Xia; Meixia Zhang
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

Review 6.  Discovery and repurposing of artemisinin.

Authors:  Qiaoli Shi; Fei Xia; Qixin Wang; Fulong Liao; Qiuyan Guo; Chengchao Xu; Jigang Wang
Journal:  Front Med       Date:  2022-03-15       Impact factor: 9.927

7.  Anti-proliferation and apoptosis-inducing effects of dihydroartemisinin on SH-SY5Y cells and metabolomic analysis.

Authors:  De-Lai Xu; Kai Fan; Hua Zhang; Liu-Xing Tang; Yang Wang; Zhen Xiang; Ai-Ming Shi; Yu-Chen Qu; Cun-Jin Su; Jie Pan
Journal:  Transl Pediatr       Date:  2022-08

Review 8.  Artemisia spp.: An Update on Its Chemical Composition, Pharmacological and Toxicological Profiles.

Authors:  Javad Sharifi-Rad; Jesús Herrera-Bravo; Prabhakar Semwal; Sakshi Painuli; Himani Badoni; Shahira M Ezzat; Mai M Farid; Rana M Merghany; Nora M Aborehab; Mohamed A Salem; Surjit Sen; Krishnendu Acharya; Natallia Lapava; Miquel Martorell; Bekzat Tynybekov; Daniela Calina; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2022-09-05       Impact factor: 7.310

9.  Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage.

Authors:  Liu-Gen Li; Xing-Chun Peng; Ting-Ting Yu; Hua-Zhen Xu; Ning Han; Xiao-Xin Yang; Qi-Rui Li; Jun Hu; Bin Liu; Zi-Yi Yang; Xiang Xu; Xiao Chen; Mei-Fang Wang; Tong-Fei Li
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988

10.  Novel dihydroartemisinin derivative Mito-DHA5 induces apoptosis associated with mitochondrial pathway in bladder cancer cells.

Authors:  Linfan Xiao; Cangcang Xu; Peiyu Lin; Lingli Mu; Xiaoping Yang
Journal:  BMC Pharmacol Toxicol       Date:  2022-01-20       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.